Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid. 1998

G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
Centro de Hematología y Medicina, Interna de Puebla, Mexico.

Six consecutive patients with promyelocytic leukaemia displaying the PML/RAR-alpha fusion messenger ribonucleic acid (mRNA)--the molecular marker of the disease--were prospectively treated with all-trans retinoic acid: Haematological complete remission was achieved in all of them. However, in three of them the PML/RAR-alpha mRNA persisted. Subsequent treatment with ablative chemotherapy rendered the molecular remission in all cases. Two of the patients that did not achieve the molecular remission with ATRA were autografted with peripheral blood stem cells after clearing the PML/RAR-alpha fusion mRNA. One patient with tretinoin-induced molecular remission relapsed two years after diagnosis and died; the remaining five survive in complete haematological and molecular remission for periods ranging from 405 to 1695 days. Additional studies are needed to clarify the significance of the molecular follow-up of patients with PML.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
September 2003, Best practice & research. Clinical haematology,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
June 1994, Australian and New Zealand journal of medicine,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
August 1998, Australian and New Zealand journal of medicine,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
August 1997, British journal of haematology,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
March 1998, British journal of haematology,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
December 1996, British journal of haematology,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
December 1996, Medical oncology (Northwood, London, England),
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
December 1992, Australian and New Zealand journal of medicine,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
December 1996, [Rinsho ketsueki] The Japanese journal of clinical hematology,
G J Ruiz-Argüelles, and J Garcés-Eisele, and A Ruiz-Argüelles
May 2013, Oman medical journal,
Copied contents to your clipboard!